Contact Dermatitis - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Contact Dermatitis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Contact Dermatitis - Pipeline Review, H1 2016', provides an overview of the Contact Dermatitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Contact Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Contact Dermatitis
- The report reviews pipeline therapeutics for Contact Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Contact Dermatitis therapeutics and enlists all their major and minor projects
- The report assesses Contact Dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Contact Dermatitis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Contact Dermatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Contact Dermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Content 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Contact Dermatitis Overview 7
Therapeutics Development 8
Pipeline Products for Contact Dermatitis - Overview 8
Contact Dermatitis - Therapeutics under Development by Companies 9
Contact Dermatitis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Contact Dermatitis - Products under Development by Companies 13
Contact Dermatitis - Companies Involved in Therapeutics Development 14
Aldeyra Therapeutics, Inc. 14
Anacor Pharmaceuticals, Inc. 15
AskAt Inc. 16
Brickell Biotech, Inc. 17
Dr. August Wolff GmbH & Co. KG Arzneimittle 18
Hapten Sciences, Inc. 19
ILiAD Biotechnologies, LLC 20
LegoChem Biosciences, Inc 21
Marinomed Biotechnologie GmbH 22
Novartis AG 23
Signum Dermalogix, Inc 24
Sucampo Pharmaceuticals, Inc. 25
Contact Dermatitis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
AAT-008 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AN-3485 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
BBI-2000 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
beta-escin - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
grapiprant - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
HPT-721 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
LCB-030110 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NS-2 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
pertussis [strain BPZE1] vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
RTU-1096 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
secukinumab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SIG-1322 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
WOL-071007 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Contact Dermatitis - Recent Pipeline Updates 57
Contact Dermatitis - Dormant Projects 71
Contact Dermatitis - Discontinued Products 72
Contact Dermatitis - Product Development Milestones 73
Featured News & Press Releases 73
Nov 19, 2015: Hapten Sciences to Begin Clinical Trials for Novel Poison Ivy Vaccine 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75

List of Tables

Number of Products under Development for Contact Dermatitis, H1 2016 8
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Contact Dermatitis - Pipeline by Aldeyra Therapeutics, Inc., H1 2016 14
Contact Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 15
Contact Dermatitis - Pipeline by AskAt Inc., H1 2016 16
Contact Dermatitis - Pipeline by Brickell Biotech, Inc., H1 2016 17
Contact Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H1 2016 18
Contact Dermatitis - Pipeline by Hapten Sciences, Inc., H1 2016 19
Contact Dermatitis - Pipeline by ILiAD Biotechnologies, LLC, H1 2016 20
Contact Dermatitis - Pipeline by LegoChem Biosciences, Inc, H1 2016 21
Contact Dermatitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2016 22
Contact Dermatitis - Pipeline by Novartis AG, H1 2016 23
Contact Dermatitis - Pipeline by Signum Dermalogix, Inc, H1 2016 24
Contact Dermatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Stage and Target, H1 2016 28
Number of Products by Stage and Mechanism of Action, H1 2016 30
Number of Products by Stage and Route of Administration, H1 2016 32
Number of Products by Stage and Molecule Type, H1 2016 34
Contact Dermatitis Therapeutics - Recent Pipeline Updates, H1 2016 57
Contact Dermatitis - Dormant Projects, H1 2016 71
Contact Dermatitis - Discontinued Products, H1 2016 72